<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Human Stem Cell Research</title>
<meta name="GENERATOR" content="HTML Transit 7.0 by Stellent (tm), Inc. www.stellent.com">
<link rel="stylesheet" type="text/css" href="/PortailStyle.css">
</head>
<body bgcolor="#ffffff"><a name="TopOfPage"> </a>
<!-- TRANSIT - INFOBEFORE -->
<table width="100%" border="0" cellpadding="4" cellspacing="0">
  <tr>
    <td><div align="left"><img src="/Documents/LogoText.jpg" width="218" height="48"></div>
    </td>
    <td><div align="right"><img border="0" SRC="/images/logos/Logo130X120.jpg" width="130" height="120"></div>
    </td>
  </tr>
</table>
<hr size="1">

<p align="justify"><b>Doc. 9942</b></p>

<p align="justify">30 September 2003</p>

<p><b>Human Stem Cell Research</b></p>

<p align="justify">Opinion</p>

<p align="justify">Social, Health and Family Affairs Committee </p>

<p align="justify">Rapporteur : Mr Bent Høie, Norway, Group of the European People&#8217;s Party</p>

<p align="justify"><b>I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conclusions of the Committee<i>  </i></b></p>

<p align="justify">For the reasons developed below, the Social, Health and Family Affairs Committee agrees with the new draft resolution presented by the Committee on Culture, Science and Education. The Committee&#8217;s opinion is based on the Assembly&#8217;s previous work on bioethics and human rights. The Committee would underline the importance of giving priority to research on adult human stem cells. The Committee would also encourage member states to establish common European programmes in this field and proposes an amendment in this sense.</p>

<p align="justify"><b>II.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Explanatory memorandum</b></p>

<p align="justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The committee would like to point out that new developments in biotechnology constantly present us with new ethical challenges. Technical progress and new discoveries relating to human embryos create expectations about the future treatment of serious diseases or the prospects for prolonging human life.</p>

<p align="justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In his report, Mr Wodarg outlines possible therapeutic use of stem cells, particularly in treatment of neurodegenerative diseases such as Parkinson&#8217;s disease and Huntington&#8217;s chorea, myocardial infarction, stroke, paralysis, epilepsy, diabetes mellitus, leukaemia and deficiencies of the immune system.</p>

<p align="justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stem cell research is expected to be equally important for basic science to understand cell differentiation and growth as well as for other specific medical applications such as for the understanding of disease development and for the development of safer and more effective drugs.</p>

<p align="justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In paragraphs 29 and 30 of the explanatory memorandum, the Rapporteur highlights the fact that the complex processes involved in the differentiation of tissues and organs are still not largely understood. Basic research, in particular with embryonic stem cells, should make a considerable contribution to understanding those mechanisms, but opinions vary amongst researchers as to whether these investigations are a necessary prerequisite for obtaining information on the way in which the differentiation of adult stem cells can be steered in particular directions, with a view to their use in regenerative cell therapy. Insofar as this research in humans reaches boundaries which must not be crossed or is rejected for ethical reasons, there remains the possibility of obtaining general information by means of animal experimental research particularly in non-human primates (monkeys).</p>

<p align="justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The controversy arises around derivation and use of embryonic stem cell lines, possible ethical distinction between &#8221;reproductive&#8221; cloning and &#8221;therapeutic&#8221; cloning<sup><a href="#P31_2725" name="P31_2726">1</a></sup>; use of &#8221;supernumerary&#8221; embryos<sup><a href="#P32_2933" name="P32_2934">2</a></sup> for research purposes; and above all, the status of the human embryo. To this regard the Committee agrees with the conclusions of the Committee on Culture, Science and Education.</p>

<p align="justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The status of the embryo is fundamental to the ethical controversy about the protection to which it should be entitled. The Rapporteur for opinion therefore draws attention to the report on &#8221;The protection<font color="#ff0000"> </font>of the human embryo <i>in vitro</i>&#8221;, which was discussed by the Steering Committee on Bioethics (CDBI) in June 2003<sup><a href="#P35_3525" name="P35_3526">3</a></sup> and which could serve as a useful basis to progress in the ethical debate on this issue.</p>

<p align="justify">7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking the above into consideration, the committee is of the opinion that human dignity should not be infringed through the differentiation of the intrinsic value of each human being. The human person is unique and has an individual right to a dignified life regardless of sex, age, race, beliefs or functional ability.</p>

<p align="justify">8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The committee considers that one individual should not be subordinated to another.  Member states&#8217; legislation should establish that each human life is an aim in itself and that no individual should be reduced to an instrument for the use of another.</p>

<p align="justify"><b>Recent developments in the European Union</b></p>

<p align="justify">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It may be useful to bring the Assembly up to date with certain relevant developments in the framework of the European Union. On 3 June 2003 the Council of the European Union reached political agreement on a common position concerning a proposal for a Directive on setting quality and safety standards for the donation, procurement, testing, processing, storage and distribution of human tissues and cells.  The common position will be formally adopted at a forthcoming Council meeting and will then be forwarded to the European Parliament for a second reading, in accordance with the co-decision procedure.  </p>

<p align="justify">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At the meeting, some delegations expressed concern about the ethical and health implications of the use of cells and tissues derived, for instance, from cloned embryos.  Moreover, the European Parliament, in its amendment proposals, had insisted that no charge should be made for donations and that there should be a ban on the use of tissues and cells derived from cloned embryos. However, the Presidency of the Council stressed that the common proposal&#8217;s implementation provisions allow member states to maintain or introduce more stringent protective measures than the ones provided for by the draft Directive, as long as they complied with the provisions of the Treaty establishing the European Communities. This would allow, in particular, member states to introduce requirements that donations of tissues and cells be voluntary and unpaid, as well as prohibiting the donation, procurement, testing, processing, preservation, storage, distribution and use of tissues and cells from specified sources such as of embryonic origin.</p>

<p align="justify">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The proposal is aimed at strengthening requirements on the suitability of donors and the screening of donated substances, while establishing national accreditation and monitoring structures and provisions for a register of accredited establishments and for a quality system for tissues and cell-related establishments.  This is seen as being particularly important in view of the fact that the transplantation of tissues and cells is a strongly expanding field of medicine, offering great opportunities for the treatment of yet incurable diseases.</p>

<p align="justify">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The proposal also aims to set up rules for ensuring the traceability of tissues and cells of human origin from donor to patient and vice versa, as well as a system for the regulation of imports of human tissues and cells from third countries, ensuring that equivalent standards of quality and safety will apply.</p>

<p align="justify">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The proposal&#8217;s provisions are applicable only to those cells and tissues that are applied to the human body in clinical trials.  Tissues and cells used for other research purposes, e.g. in <i>in vitro</i> research or in animal models, are not covered by the proposed Directive.<sup><a href="#P52_7199" name="P52_7200">4</a></sup></p>

<p align="justify">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In July 2003 the European Commission adopted a proposal for guidelines on EU-funded human embryonic stem cell research<sup><a href="#P54_7408" name="P54_7409">5</a></sup>. The EU 6th Research Framework Programme, as adopted by the Council of Ministers and the European Parliament in 2002, allows for the funding of human embryonic stem cell research in relation to the fight against major diseases. Such research, in particular when it involves the derivation of stem cells from human supernumerary embryos, can only take place within a framework of clear and strict ethical guidelines.</p>

<p align="justify">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In light of the sensitive nature of human embryonic stem cell research, the Council of the European Union and the European Commission agreed that further ethical guidelines would be adopted before the end of 2003 for deciding on and for monitoring the EU funding of human embryonic stem cell research. The European Commission&#8217;s proposal presents a coherent set of strict ethical guidelines that will apply to the EU funding of research projects involving the derivation of stem cells from human supernumerary embryos. </p>

<p align="justify">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On Monday 22 September 2003, the EU Research Ministers opened a discussion on the Commission proposals which should be concluded by 31 December 2003<sup><a href="#P57_8677" name="P57_8678">6</a></sup>. </p>

<p align="justify">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In parallel, the Commission is publishing a call for proposals for the set-up of a European registry of stem cells and for contributing to the establishment of public stem cell banks. In this way, the EU would contribute to an optimal access to and use of stem cells, ensuring that the results of research ultimately become more quickly available to all patients across Europe. </p>

<p align="justify"><b>III.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amendment proposed by the Social, Health and Family Affairs Committee to the draft resolution in Doc. 9902</b></p>

<p align="justify">In paragraph 11, add a new sub-paragraph following sub-paragraph iii. to read as follows:</p>

<p align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;promote common European basic research programmes in the field of adult stem cells;&#8221;**</p>

<p align="justify">*</p>

<p align="justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*        *</p>

<p align="justify"><i>Reporting committee: Committee on Culture, Science and Education (<a href="/ASP/Doc/RefRedirectEN.asp?Doc=Doc. 9902">Doc. 9902</a>)</i></p>

<p align="justify"><i>Committee for opinion: Social, Health and Family Affairs Committee</i></p>

<p align="justify"><i>Reference to committee: <a href="/ASP/Doc/RefRedirectEN.asp?Doc=Doc. 9851">Doc. 9851</a>, Ref. 2767, 18.11.02</i></p>

<p align="justify">Opinion approved by the committee on 29 September 2003</p>

<p align="justify">Committee Secretariat: Mr Mezei, Mrs Meunier, Mrs Karanjac and Mr Chahbazian</p>
<hr align="left" size="1" width="200" noshade>

<p align="justify"><sup><a name="P31_2725" href="#P31_2726">1</a> </sup> Cells created by cell nucleus transfer which could serve for the creation of embryonic stem cells with the generic characteristics of a patient for therapeutic purposes.</p>

<p align="justify"><sup><a name="P32_2933" href="#P32_2934">2</a> </sup> Embryos, created by fertilization <i>in vitro</i>, that are no longer part of a parental project</p>

<p align="justify"><sup><a name="P35_3525" href="#P35_3526">3</a> </sup></p>

<p align="justify"> Council of Europe : &#8220;The protection of the human embryo in vitro&#8221;, report by the Working Party on the Protection of the Human Embryo and Foetus, CDBI-CO-GT3 (2003) 13, June 2003</p>

<p align="justify"><sup><a name="P52_7199" href="#P52_7200">4</a> </sup> Council of the European Communities, 2/3.VI.2003; Communiqué, 9688/03 (Presse 152) 7</p>

<p align="justify"><sup><a name="P54_7408" href="#P54_7409">5</a> </sup> European Commission, press release, DN:IP/03/969, 9 July 2003 : &#8220;European Commission proposes strict ethical guidelines on EU funding of human embryonic stem cell research&#8221;</p>

<p align="justify"><sup><a name="P57_8677" href="#P57_8678">6</a> </sup> «&nbsp;Le financement de la recherche sur les cellules-souches embryonnaires divise les Européens&nbsp;», article&nbsp;in «&nbsp;Le Monde&nbsp;», 24.09.2003&nbsp;</p><!-- TRANSIT - INFOAFTER -->
</body>
</html>
